================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) December 2, 2004
HAEMONETICS CORPORATION
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Massachusetts 1-10730 04-2882273
---------------------------- ---------------- -------------------
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
400 Wood Road Braintree, MA 02184
---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (781) 848-7100
------------------------------------------------------------
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[_] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Page 1 of 16
Section 1 - Regristrant's Business and Operations
Item 1.01 Entry into a Material Definitive Agreement.
An Executive Employment agreement was entered into on December
2, 2004, effective November 1, 2004, between Ulrich Eckert and
Haemonetics S.A, a Swiss company and wholly-owned subsidiary
of Haemonetics Corporation. Reference is made to the Executive
Employment agreement filed as Exhibit 10 hereto for a
description of the terms of such agreement.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
10: An Executive Employment agreement was entered into on
December 2, 2004, effective November 1, 2004, between Ulrich
Eckert and Haemonetics S.A, a Swiss company and wholly-owned
subsidiary of Haemonetics Corporation.
Page 2 of 16
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Haemonetics Corporation
Date: December 2, 2004 By: /s/ Ronald J. Ryan
------------------------------
Ronald J. Ryan, Vice President and
Chief Financial Officer
Page 3 of 16
EXHIBIT INDEX
Exhibit No. Subject Matter
----------- --------------
10 An Executive Employment agreement was entered into on December
2, 2004, effective November 1, 2004, between Ulrich Eckert and
Haemonetics S.A, a Swiss company and wholly-owned subsidiary
of Haemonetics Corporation.
Page 4 of 16